



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville, MD 20857

ANDA 091020

Navinta LLC
Attention: Pankaj Dave, Ph.D.
Vice President, Regulatory Affairs
1499 Lower Ferry Road
Ewing, NJ 08618

Dear Sir:

This is in reference to your abbreviated new drug application (ANDA) dated November 8, 2008, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Famotidine for Oral Suspension USP, 40 mg/5 mL (400 mg/50 mL upon constitution).

Reference is also made to your amendments dated March 17, March 24, April 10, May 7, July 6, and December 29, 2009; January 19, February 15 and February 17, 2010.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the ANDA is approved, effective on the date of this letter. The Division of Bioequivalence has determined your Famotidine for Oral Suspension USP, 40 mg/5 mL to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Pepcid Oral Suspension, 40 mg/5 mL, of Salix Pharms. Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.

Under section 506A of the Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

We note that if FDA requires a Risk Evaluation & Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS, See 505-1(i).

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Division of Drug Marketing, Advertising, and Communications with a completed Form FDA 2253 at the time of their initial use.

Within 14 days of the date of this letter, submit updated content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical in content to the approved labeling. For administrative purposes, please designate this submission as "**Miscellaneous Correspondence - SPL for Approved ANDA 091020**".

Sincerely yours,

{See appended electronic signature page}

Keith Webber, Ph.D.
Deputy Director
Office of Pharmaceutical Science
Center for Drug Evaluation and Research

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
-----	-----	-----	-----
ANDA-91020	ORIG-1	NAVINTA LLC	FAMOTIDINE

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ROBERT L WEST

05/27/2010

Deputy Director, Office of Generic Drugs
for Keith Webber, Ph.D.